Supernus Pharmaceuticals, Inc.
(NASDAQ : SUPN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
-0.99%174.950.4%$344.99m
AMRNAmarin Corporation Plc Sponsored ADR
-3.78%16.062.0%$149.53m
JAZZJazz Pharmaceuticals Plc
-1.08%140.562.2%$114.91m
PRGOPerrigo Co. Plc
-2.58%57.006.8%$67.38m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-1.10%119.536.3%$53.66m
MNKMallinckrodt Plc
-7.64%19.2321.1%$53.07m
ICLRICON Plc
-1.99%133.504.1%$46.79m
UTHRUnited Therapeutics Corporation
-2.05%107.8914.4%$42.00m
ICPTIntercept Pharmaceuticals, Inc.
-0.07%108.0118.6%$39.25m
SAGESAGE Therapeutics, Inc.
1.36%101.999.6%$36.88m
HZNPHorizon Pharma plc
0.25%19.937.4%$35.80m
ENDPEndo International Plc
-8.53%10.198.9%$33.99m
CTLTCatalent Inc
-3.91%34.642.4%$30.89m
MDCOMedicines Company
-3.54%19.0621.8%$26.60m
ZGNXZogenix, Inc.
-1.03%41.449.9%$24.77m

Company Profile

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.